Liquidia (LQDA) Cash from Operations Growth (1y) (2021 - 2026)
Liquidia (LQDA) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.49 Bn | 30.55 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.13 Bn | 20.97 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 425.00% |
| 10 | Liquidia | 7.62 Bn | 7.39 Bn | 121.79 Mn | 272.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 272.72% |
| Dec 31, 2025 | 312.58% |
| Sep 30, 2025 | 61.05% |
| Jun 30, 2025 | -74.22% |
| Mar 31, 2025 | -23.38% |
| Dec 31, 2024 | -30.23% |
| Sep 30, 2024 | -116.95% |
| Jun 30, 2024 | -307.28% |
| Mar 31, 2024 | -194.03% |
| Dec 31, 2023 | -247.21% |
| Sep 30, 2023 | -100.23% |
| Jun 30, 2023 | 33.99% |
| Mar 31, 2023 | 13.55% |
| Dec 31, 2022 | 39.11% |
| Sep 30, 2022 | 0.98% |
| Jun 30, 2022 | -2.06% |
| Mar 31, 2022 | 21.02% |
| Dec 31, 2021 | 46.34% |
| Sep 30, 2021 | 53.39% |
| Jun 30, 2021 | 37.00% |